Latest Earnings Results: Q2 '26
Estimated EPS
$0.06
Reported EPS
$0.11
Surprise
+83.33%
Estimated Rev
$26.36M
Reported Rev
$28.25M
Surprise
+7.18%
• Reported GAAP EPS of $0.12 up 300.00% YoY • Reported revenue of $28.25M up 48.08% YoY • Paysign expects full-year 2026 revenue of $114.0 million to $117.0 million and Adjusted EBITDA of $35.0 million to $38.0 million, reflecting momentum across the business and anticipated additional program launches.
Bullish Takeaway
Paysign delivered record revenue and improved margins in Q2 2026, supported by strong growth in its pharma patient affordability programs and a solid balance sheet with zero debt for future investments.
Bearish Takeaway
Paysign faces risks from a declining net plasma center count, rising operating and stock-based compensation expenses, and potential regulatory shifts that could negatively impact its patient affordability and copay assistance business.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.06 | -- | -- | N/A |
Q2 '26 | $0.06 | $0.11 | 83.33% | BEAT |
Q1 '26 | $0.07 | $0.09 | 28.57% | BEAT |
Q4 '25 | $0.02 | $0.02 | -- | EXPECTED |
Q3 '25 | $0.02 | $0.04 | 100.00% | BEAT |